← Back to Screener
SCYNEXIS, Inc. (SCYX)
Price$4.71
Value ScoreA
Growth ScoreA
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-22.60%
Price vs S&P 500 (4W)-35.73%
VGM Score69.57
Market Capitalization$46.77M
All Metrics
Book Value / Share (Quarterly)$5.33
P/TBV (Annual)1.14x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)59.36%
Cash Flow / Share (Quarterly)$-0.76
Price vs S&P 500 (YTD)-15.07%
Gross Margin (TTM)100.00%
Net Profit Margin (TTM)-41.79%
EPS (TTM)$-2.92
10-Day Avg Trading Volume0.08M
EPS Excl Extra (TTM)$-2.92
Revenue Growth (5Y)99.01%
EPS (Annual)$-1.38
ROI (Annual)-17.44%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-409.20%
Cash / Share (Quarterly)$7.64
Revenue Growth QoQ (YoY)1808.50%
ROA (Last FY)-14.58%
Revenue Growth TTM (YoY)673.54%
EBITD / Share (TTM)$-1.42
ROE (5Y Avg)-401.32%
Operating Margin (TTM)-77.93%
Cash Flow / Share (Annual)$-0.97
P/B Ratio1.13x
P/B Ratio (Quarterly)0.99x
Net Income / Employee (Annual)$-478,300
EV / Revenue (TTM)0.49x
Net Interest Coverage (TTM)31.96x
ROA (TTM)-39.48%
EV / EBITDA (TTM)0.14x
EPS Incl Extra (Annual)$-1.38
Current Ratio (Annual)7.04x
Quick Ratio (Quarterly)3.92x
3-Month Avg Trading Volume0.07M
52-Week Price Return-33.57%
Revenue / Employee (TTM)$1,130,200
Tangible BV / Share (Quarterly)$1.96
P/S Ratio (Annual)2.27x
Asset Turnover (Annual)0.35x
52-Week High$10.48
Operating Margin (5Y Avg)-636.97%
EPS Excl Extra (Annual)$-1.38
Tangible BV CAGR (5Y)-33.31%
26-Week Price Return-14.67%
Quick Ratio (Annual)7.00x
13-Week Price Return-25.71%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.94x
Enterprise Value$10.10M
Revenue / Share Growth (5Y)29.25%
Asset Turnover (TTM)0.35x
Book Value / Share Growth (5Y)51.09%
Revenue / Employee (Annual)$1,144,500
Inventory Turnover (Annual)0.92x
Pretax Margin (Annual)-41.79%
Cash / Share (Annual)$7.36
3-Month Return Std Dev74.00%
Gross Margin (5Y Avg)75.47%
Net Income / Employee (TTM)$-1,362,100
ROE (Last FY)-17.44%
Net Interest Coverage (Annual)8.40x
EPS Basic Excl Extra (Annual)$-1.38
P/FCF (TTM)2.54x
Receivables Turnover (TTM)133.52x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.92
Receivables Turnover (Annual)133.47x
ROI (TTM)-57.16%
P/S Ratio (TTM)2.27x
Pretax Margin (5Y Avg)-431.52%
Revenue / Share (Annual)$3.30
Tangible BV / Share (Annual)$15.69
Price vs S&P 500 (52W)-57.93%
Year-to-Date Return-6.92%
5-Day Price Return-11.63%
EPS Normalized (Annual)$-1.38
ROA (5Y Avg)-16.97%
Net Profit Margin (Annual)-41.79%
Month-to-Date Return-16.49%
EBITD / Share (Annual)$-2.58
Operating Margin (Annual)-78.03%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-27.82%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.92
P/TBV (Quarterly)1.14x
P/B Ratio (Annual)0.54x
Inventory Turnover (TTM)34.63x
Pretax Margin (TTM)-41.79%
Book Value / Share (Annual)$9.07
Price vs S&P 500 (13W)-33.96%
Beta1.10x
P/FCF (Annual)0.78x
Revenue / Share (TTM)$3.19
ROE (TTM)-57.16%
52-Week Low$4.52
vGradeA
gGradeA
mGradeD
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-3.36est. -1.01
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.22
4.22
4.22
4.22
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SCYXSCYNEXIS, Inc. | A | A | D | $4.71 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
SCYNEXIS develops novel antifungal therapies to treat serious fungal infections with significant unmet medical needs. The company's lead candidate, ibrexafungerp, is an oral and intravenous glucan synthase inhibitor demonstrating broad-spectrum activity against drug-resistant Candida and Aspergillus species. The medication's differentiated mechanism of action offers potential advantages over existing antifungal treatments for invasive fungal infections.